Vanda Pharmaceuticals (NASDAQ:VNDA) Rating Increased to Hold at Wall Street Zen

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday.

Several other brokerages also recently commented on VNDA. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ VNDA traded down $0.09 during mid-day trading on Friday, reaching $4.49. 796,913 shares of the company traded hands, compared to its average volume of 635,976. The stock has a market cap of $264.60 million, a PE ratio of -5.99 and a beta of 0.66. The company's fifty day moving average is $4.33 and its two-hundred day moving average is $4.54. Vanda Pharmaceuticals has a fifty-two week low of $3.81 and a fifty-two week high of $6.46.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.05. The company had revenue of $50.04 million for the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative return on equity of 8.30% and a negative net margin of 21.98%. Research analysts forecast that Vanda Pharmaceuticals will post -1.12 earnings per share for the current year.

Insider Activity

In other news, CEO Mihael Hristos Polymeropoulos acquired 20,000 shares of the stock in a transaction dated Friday, May 16th. The shares were acquired at an average cost of $4.22 per share, for a total transaction of $84,400.00. Following the completion of the transaction, the chief executive officer now owns 2,315,731 shares in the company, valued at approximately $9,772,384.82. This trade represents a 0.87% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Stephen Ray Mitchell sold 7,000 shares of the business's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $4.59, for a total value of $32,130.00. Following the sale, the director now owns 97,082 shares in the company, valued at approximately $445,606.38. This represents a 6.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.90% of the stock is currently owned by company insiders.

Institutional Trading of Vanda Pharmaceuticals

Several institutional investors have recently bought and sold shares of VNDA. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Vanda Pharmaceuticals by 4.9% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company's stock valued at $3,925,000 after buying an additional 38,449 shares in the last quarter. Monaco Asset Management SAM boosted its stake in Vanda Pharmaceuticals by 92.8% in the 4th quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company's stock valued at $1,879,000 after buying an additional 188,836 shares in the last quarter. American Century Companies Inc. boosted its stake in Vanda Pharmaceuticals by 2.1% in the 4th quarter. American Century Companies Inc. now owns 300,276 shares of the biopharmaceutical company's stock valued at $1,438,000 after buying an additional 6,079 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Vanda Pharmaceuticals in the 4th quarter valued at $649,000. Finally, JPMorgan Chase & Co. boosted its stake in Vanda Pharmaceuticals by 108.9% in the 4th quarter. JPMorgan Chase & Co. now owns 335,741 shares of the biopharmaceutical company's stock valued at $1,608,000 after buying an additional 175,019 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company's stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.